Skip to content

OptiNose, Inc.

Delisted

CIK 1494650fmd_0X1V9E5Q25Q5JNK1SACX973ZV3Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Mar 31, 2025, 38 periods

Latest annual · FY2024

Millions
Total revenues
78
Gross profit
71
Operating income
(16)
Net income
(22)
Free cash flow
(45)

Latest quarter · Q1 FY2025

Millions
Total revenues
19
Gross profit
17
Operating income
(8)
Net income
(22)
Free cash flow
(12)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2021 to FY2024
+1.6%
Revenue, 5 yearsFY2019 to FY2024
+17.7%
Net income, 5 yearsFY2019 to FY2024
n/m

OptiNose, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2024FY2023ChangeSource
Revenue$78.2 million$71 million+10.2%10-K 2025-03-26 · proof
Gross profit$71 million$62.4 million+13.9%10-K 2025-03-26 · proof
Operating income-$16.3 million-$22.7 million10-K 2025-03-26 · proof
Net income-$21.5 million-$35.5 million10-K 2025-03-26 · proof
Cash from operating activities-$44.7 million-$20.5 million10-K 2025-03-26 · proof
Free cash flow-$44.8 million-$20.9 million10-K 2025-03-26 · proof
Total assets$128.8 million$107.7 million+19.5%10-K 2025-03-26 · proof
Total liabilities$169.1 million$194.3 million-13%10-K 2025-03-26 · proof
Cash and cash equivalents$84.5 million$73.7 million+14.7%10-K 2025-03-26 · proof
What was OptiNose, Inc.'s revenue in fiscal 2024?
OptiNose, Inc. reported revenue of $78.2 million for fiscal 2024 (the year ended Dec 31, 2024), against $71 million the year before (+10.2%). Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What was OptiNose, Inc.'s gross profit in fiscal 2024?
OptiNose, Inc. reported gross profit of $71 million for fiscal 2024 (the year ended Dec 31, 2024), against $62.4 million the year before (+13.9%). Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What was OptiNose, Inc.'s operating income in fiscal 2024?
OptiNose, Inc. reported operating income of -$16.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$22.7 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What was OptiNose, Inc.'s net income in fiscal 2024?
OptiNose, Inc. reported net income of -$21.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$35.5 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What was OptiNose, Inc.'s cash from operating activities in fiscal 2024?
OptiNose, Inc. reported cash from operating activities of -$44.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$20.5 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What was OptiNose, Inc.'s free cash flow in fiscal 2024?
OptiNose, Inc. reported free cash flow of -$44.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$20.9 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What are OptiNose, Inc.'s total assets?
As of Dec 31, 2024, OptiNose, Inc. reported total assets of $128.8 million, against $107.7 million a year earlier (+19.5%). Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What are OptiNose, Inc.'s total liabilities?
As of Dec 31, 2024, OptiNose, Inc. reported total liabilities of $169.1 million, against $194.3 million a year earlier (-13%). Source: the 10-K filed with the SEC on Mar 26, 2025. SEC
What are OptiNose, Inc.'s cash and cash equivalents?
As of Dec 31, 2024, OptiNose, Inc. reported cash and cash equivalents of $84.5 million, against $73.7 million a year earlier (+14.7%). Source: the 10-K filed with the SEC on Mar 26, 2025. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1494650&period_type=annual&limit=5"

Information only, not investment advice.